A recent study suggests that interleukin-31 (IL-31) exerts its effect via indirect mechanisms rather than through direct stimulation of cutaneous nerves. However, the underlying peripheral mechanisms of IL-31-induced itch in the skin remain unclear. Therefore, the present study investigated the peripheral mechanisms underlying IL-31-induced itch in mice. IL-31-induced itch-related response was inhibited by anti-allergic drugs (tranilast and azelastine), but not by an H1 histamine receptor antagonist (terfenadine). Furthermore, a 5-lipoxygenase inhibitor (zileuton), but not a cyclooxygenase inhibitor (indomethacin), and a leukotriene B4 (LTB4) receptor antagonist (CMHVA) attenuated the action of IL-31. IL-31 receptor-immunoreactivity was observed in the epidermis and primary sensory neurones. IL-31 receptor mRNA was expressed in mouse keratinocytes and dorsal root ganglia neurones. IL-31 increased the production of LTB4 in mouse keratinocytes. These results suggest that IL-31 elicits itch not only through direct action on primary sensory neurones, but also by inducing LTB4 production in keratinocytes.

Key words: itch; leukotriene B4; interleukin-31; keratinocytes; scratching; dorsal root ganglia.

Accepted May 16, 2017; Epub ahead of print May 17, 2017

Corr: Tsugunobu Andoh, Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Involvement of Leukotriene B4 Released from Keratinocytes in Itch-associated Response to Intradermal Interleukin-31 in Mice

Tsunobu ANDOH, Ayako HARADA and Yasushi KURAISHI
Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Involvement of Leukotriene B4 Released from Keratinocytes in Itch-associated Response to Intradermal Interleukin-31 in Mice

Tsunobu ANDOH, Ayako HARADA and Yasushi KURAISHI
Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

MATERIALS AND METHODS

Animals

Male ICR mice aged 4–11 weeks were used in this study. The mice were purchased from Japan SLC (Shizuoka, Japan). For one part of the experiment, neonatal mice were used for the isolation of cutaneous keratinocytes. Neonatal mice were obtained from late pregnant mice purchased from Japan SLC (Shizuoka). They were housed in a room with controlled temperature (21–23°C), humidity (45–65%), and light (on from 07.00h to 19.00h). Food and water were freely available. All experimental procedures involving animals were approved by the Committee for Animal Experiments at the University of Toyama and conducted in accordance with the guidelines of the Japanese Pharmacological Society.

Drugs

Recombinant mouse IL-31 was prepared in Chugai Pharmaceutical Co., Ltd (Shizuoka, Japan). Briefly, IL-31 was purified from the supernatant of mouse IL-31-transformed Chinese hamster ovary cells using hydroxyapatite column (Bio-Rad Laboratories, Inc., Hercules, CA, USA), ion-exchange column (GE healthcare, Chicago, IL, USA), and gel filtration column (GE healthcare). IL-31 was dis-
The fluorescence signals were observed using a confocal laser-scanning microscope and Alexa Fluor 488-conjugated anti-goat IgG antibodies (Life Technologies, USA) at 4°C overnight. After washing, the preparations were incubated with gene product 9.5 antibody (RA95101; 1:2000, Ultraclone Ltd, Isle of Wight, UK) and rabbit anti-protein gene product 9.5 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and non-specific IgG antibody (Sigma-Aldrich) at 4°C overnight. Anti-IL-31RA antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and non-specific IgG antibody (Sigma-Aldrich) were treated 60 min before IL-31 application. Anti-IL-31RA antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and non-specific IgG antibody (Sigma-Aldrich) were treated 30 min before IL-31 injection.

**Immunohistochemistry**

Under anaesthesia with pentobarbital (80 mg/kg, intraperitoneal), the mice were transcardially perfused with PBS and then 4% paraformaldehyde (PFA). The rostral back skin was isolated and post-fixed with 4% PFA at 4°C overnight. The skin was immersed in 30% sucrose solution at 4°C for at least 2 days. The tissue was embedded in Tissue-Tek® optimum cutting temperature (OCT) compound (Sakura Fineteck Co., Ltd, Tokyo) and stored at −80°C until use. The frozen sections were sectioned at 20 μm with a cryostat (Leica, Wetzlar, Germany). After being washed with PBS 3 times, the sections were treated with 0.3% Triton X-100 in PBS to block non-specific immunoglobulin binding. The sections were incubated with goat anti-IL-31 receptor A (IL-31RA) antibody (AF2107; 1:500, R&D Systems, Inc., Minneapolis, MN, USA) and rabbit anti-protein gene product 9.5 antibody (RA95101; 1:2000, Ultraclone Ltd, Isle of Wight, UK) at 4°C overnight. After washing, the preparations were incubated with Alexa Fluor 594-conjugated anti-rabbit IgG and Alexa Fluor 488-conjugated anti-goat IgG antibodies (Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature. The fluorescence signals were observed using a confocal laser-scanning microscope (Bio-Rad Laboratories Inc., Hercules, USA).

**Primary cultures of murine keratinocytes and dorsal ganglion neurones**

The skin from neonatal mice was removed and treated with 0.05% collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) dissolved in serum-free MCDB 153 medium (Sigma-Aldrich) containing 0.67% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Dojindo, Kumamoto, Japan), 0.12% sodium bicarbonate (Wako Pure Chemical Industries Ltd) and 0.006% kaolin (Meiji Seika Pharma Co., Ltd, Tokyo, Japan), and 0.006% kaolin (Wako Pure Chemical Industries Ltd) at 37°C overnight. The epidermal sheets were peeled gently from the underlying dermis. The keratinocytes were dissociated by gently shaking the serum-free MCDB 153 medium containing the epidermal sheet. After washing with keratinocyte growth medium (CELLnTEC Advanced Cell Systems AG, Bern, Switzerland), the keratinocytes were cultured in collagen-coated 24-well or 6-cm-diameter plates.

The bilateral DRGs at C1–T13 levels were removed from the 6-week-old mice. DRG was treated with 0.25% collagenase (Wako Pure Chemical Industries Ltd) in serum-free Dulbecco’s Modified Eagle’s medium (DMEM) containing antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) at 37°C for 1 h and was shaken gently for dissociation. The dissociated cells were treated with 0.25% trypsin-EDTA at 37°C for 15 min and then the cells were washed with DMEM containing antibiotics. The cells were suspended in DMEM containing antibiotics, 10% foetal bovine serum, and 50 μM cytosine β-D-arabinofuranoside (Sigma-Aldrich), and cultured in poly-D-lysine-coated 6-cm-diameter plates.

**Reverse transcription and PCR**

The total RNA from the primary cultures of murine keratinocytes and DRG neurones was extracted by using GeneElute Mammalian Total RNA mini prep kit (Sigma-Aldrich). The total RNA (1 μg) was reverse transcribed into the cDNA using oligo (dT)₁₆ primer and Reverscript III® (Wako Pure Chemical Industries Ltd). PCR was performed as described previously (16). The primer sequences used were as follows: IL-31RA (sense) 5′-tgctgctatgccgag-3′; IL-31RA (antisense) 5′-taatgctgctatgccgag-3′; OSMRβ (sense) 5′-tacaagggctgctagctga-3′; OSMRβ (antisense) 5′-aagttctctctctccg-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sense) 5′-cctctggatcgcagac-3′; GAPDH (antisense) 5′-ttaccctctttgagaggt-3′. The reaction product was separated on 2% agarose gel and stained with ethidium bromide.

**Measurement of LTB₄**

To measure LTB₄ production in keratinocytes, the culture medium (200 μl) was collected (removed) from the primary cultures of murine keratinocytes 10 min after IL-31 administration and assayed for LTB₄ with an enzyme immunoassay (ELA) kit (Cayman Chemical, Ann Arbor, MI, USA). Zileuton and the vehicle (dime-thyl sulphoxide, final concentration 0.001%) were treated 60 min before IL-31 application. Anti-IL-31RA antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and non-specific IgG (Sigma-Aldrich) were treated 30 min before IL-31 application. The remaining keratinocytes were treated with 1% Triton X-100 and used for protein determination by using a protein assay kit (Bio-Rad Laboratories, Inc.). The amount of LTB₄ was normalized to the amount of protein.

**Data processing**

Data are presented as means ± standard error of the mean (SEM). The statistical significance was analysed using the Student’s t-test (2 groups), one-way analysis of variance (ANOVA), or 2-way repeated measures-ANOVA followed by a post hoc Holm–Šidák test (3 or more groups). A p-value < 0.05 was considered statistically significant.

**RESULTS**

**Scratching behaviour induced by IL-31**

An intradermal injection of IL-31 (100 ng/site), but not vehicle, into the rostral back elicited hind-paw scratching directed towards the injection site (Fig. 1A). This effect peaked during the first 10 min. Compared with the
treatment of vehicle (PBS) control, IL-31 (100 ng/site)-induced scratching increased significantly from 10 min after the injection, and the significant effects continued for at least 50 min (Fig. 1A). The dose-response curve for IL-31 was bell-shaped (Fig. 1B).

**Effects of various drugs on IL-31-induced scratching**

The effects of systemic pretreatment on the scratching induced by an intradermal injection of IL-31 (100 ng/site) were examined by using several agents. The μ-opioid receptor antagonist naltrexone hydrochloride (1 and 10 mg/kg) significantly inhibited IL-31-induced scratching (Fig. 2). The H1 histamine receptor antagonist, terfenadine (30 mg/kg), did not exhibit any effect on scratching (Fig. 2). The anti-allergic agents tranilast (100 and 300 mg/kg; Fig. 2) and azelastine hydrochloride (30 mg/kg; Fig. 2) inhibit IL-31-induced scratching. The 5-lipoxygenase inhibitor, zileuton (30 and 100 mg/kg), inhibited IL-31-induced scratching, whereas the cyclooxygenase inhibitor indomethacin (10 mg/kg) did not (Fig. 3). The LTB4 receptor antagonist CMHVA (10, 30 and 100 mg/kg) also attenuated IL-31-induced scratching (Fig. 3). Naltrexone hydrochloride (10 mg/kg), tranilast (30 mg/kg), azelastine hydrochloride (30 mg/kg), zileuton (100 mg/kg, p.o.), and CMHVA (100 mg/kg) did not affect the spontaneous locomotor activity, suggesting that these drugs at the dosage used do not have sedative effects (Fig. S1)

**Distribution of IL-31 receptor A in the mouse skin, and the expression of IL-31 receptor mRNA in the mouse skin, dorsal root gangleon (DRG), and primary cultures of DRG neurones and keratinocytes**

IL-31RA immunoreactivity was mainly localized in the epidermis and PGP-9.5-immunoreactive primary afferents (Fig. 4A).

The RT-PCR revealed the substantial expression of IL-31RA and OSMRβ mRNA in the DRG and skin (Fig. 4B). In addition, the primary cultures of DRG neurones and keratinocytes also expressed both IL-31RA and OSMRβ mRNA (Fig. 4B).

**IL-31-induced production of LTB4 in primary cultures of mouse keratinocytes**

A bath-application of IL-31 (0.2 and 2 μg/ml) to the primary cultures of mouse keratinocytes significantly increased the production of LTB4 (Fig. 5A). The effect of IL-31 (2 μg/ml) was almost abolished by the 5-lipoxygenase inhibitor zileuton (10 μM; Fig. 5A). In addition, anti-IL-31RA antibody (10 μg/ml) significantly inhibited IL-31-induced LTB4 production (Fig. 5B).

**DISCUSSION**

This study aimed to demonstrate peripheral mechanisms of IL-31-induced itch and found that IL-31-induced itch...
through the production of LTB₄ in epidermal keratinocytes.

An intradermal injection of IL-31 elicited scratching at the injection site. Next, it was examined whether scratching in mice was an itch-related behaviour. The scratching was inhibited by the μ-opioid receptor antagonist naltrexone. μ-Opioid receptor antagonists inhibit the scratching induced by several pruritogens (e.g. substance P, sphingosylphosphorylcholine, serotonin, gastrin-releasing peptide, and α-melanocyte-stimulating hormone) (18–20, 27, 28), dermatoses (e.g. skin allergy, atopic dermatitis and xerosis) in rodents (29–31), and itching/scratching in humans with pruritic diseases (e.g. cholestasis, urticaria and atopic dermatitis) (32, 33). μ-Opioid receptor antagonists suppress itch-associated behaviour without inhibiting the pain-related behaviour (34, 35). The opioid antagonists may inhibit itching/scratching by acting on the μ-opioid receptors in the central nervous system, especially in the lower brainstem (36–39). Thus, it can be suggested that IL-31-induced scratching is an itch-associated response in mice.

It has been reported that IL-31 acts directly on primary afferent neurones (13). In this study, although an intradermal administration of IL-31 elicited scratching with the effect peaking during the first 10-min period, the significant effect of IL-31 continued for another 50 min after the attainment of peak effect, suggesting that IL-31 affects not only directly, but also indirectly, primary afferent neurones.

The H₁ histamine receptor antagonist terfenadine (30 mg/kg) inhibited histamine-induced scratching in mice (30). However, the same dosage of terfenadine did not affect IL-31-induced scratching, suggesting that histamine may not play an important role in scratching. However, anti-allergic drugs (tranilast and azelastine) attenuated IL-31-induced scratching. Tranilast has an inhibitory action on the production of LTB₄ (40). In addition to H₁, histamine receptor antagonistic activity, azelastine has an inhibitory effect on LTB₄ production and LTB₄ receptor antagonistic activity (22). The IL-31-induced scratching was inhibited by 5-lipoxygenase inhibitor zileuton and LTB₄ receptor antagonist CMHVA. However, the cyclooxygenase inhibitor indomethacin did not show any effect on scratching. An intradermal injection of LTB₄, but not prostaglandin E₂, elicits scratching in mice (41). Taken together, these findings suggest that LTB₄ is involved in IL-31-induced scratching.

5-Lipoxygenase is a key enzyme involved in the production of LTB₄ (42). In the skin, 5-lipoxygenase is

---

Fig. 4. Distribution of interleukin-31 receptor A (IL-31RA) in the mouse skin and the expression of IL-31 receptors mRNA. (A) The typical examples of the distribution of IL-31 receptor A (IL-31RA) and primary afferent neurones in the mouse skin. IL-31RA (green) and PGP-9.5 (red, a marker of neurone) were immunostained in the rostral back skin. Arrowheads indicate primary sensory neurones, and the dotted lines indicates the boundary between the dermis and epidermis. Scale bar = 100 μm. (B) The expression of IL-31 receptor (IL-31RA and OSMRβ) mRNA in the mouse skin, dorsal root ganglion (DRG), and primary cultures of DRG neurones and keratinocytes. IL-31RA, OSMRβ, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNAs were determined using RT-PCR.

Fig. 5. Interleukin (IL)-31-induced leukotriene B₄ (LTB₄) production in the primary cultures of keratinocytes. (A) IL-31-induced production of LTB₄ and effect of 5-lipoxygenase inhibitor zileuton on LTB₄ production. Zileuton (10 μM) or the vehicle (VH2) was treated 60 min before IL-31 or the vehicle (VH2) application. The concentration of LTB₄ in the tested medium was determined 10 min after IL-31 application. Data are presented as mean and standard error of the mean (SEM) (n = 18). *p < 0.05 compared with that of VH1+VH2 (Holm–Šidák test). (B) Effect of anti-IL-31RA on IL-31-induced LTB₄ production. Anti-31RA antibody (anti-31RA, 10 μg/ml) or non-specific immunoglobulin G (IgG) (nIgG, 10 μg/ml) were treated 30 min before IL-31 (2 μg/ml) or VH2. The concentration of LTB₄ in the tested medium was determined 10 min after IL-31 application. Data are presented as mean and SEM (n = 6). *p < 0.05 compared with that of nIgG+VH2 (Holm–Šidák test).
expressed mainly in the keratinocytes (43) and mast cells (44). IL-31 receptors are expressed in the keratinocytes, but not in the mast cells (4, 6, 45; Fig. 4 and Fig. S2A). In addition, an intradermal injection of IL-31 elicited scratching in mast cell-deficient mice and the normal littermates (Fig. S2B). Therefore, it is suggested that the mast cells are not involved in IL-31-induced LTB₄ production. Our previous report showed that an intradermal injection of proteinase-activated receptor-2 (PAR2) agonist SLIGRL-NH₂ (peptidergic agonist) induced LTB₄ production (46). PAR2 is mainly expressed in the keratinocytes in the skin (25). These findings suggest that intradermal pruritogens including IL-31 act on the epidermal keratinocytes. In this study, IL-31 induced LTB₄ production in the primary cultures of mouse keratinocytes. In this study, IL-31-induced LTB₄ production in keratinocytes remain unclear. IL-31 activates 3 signalling pathways: Jak/STAT pathway, PI3K/AKT pathway, and MAPK pathway (47). However, whether these pathways are involved in the production of LTB₄ remain unknown. IL-31 also increases the intracellular Ca²⁺ concentration in keratinocytes (48). The increase in intracellular free Ca²⁺ ions activates phospholipase A₂, a key enzyme for the production of arachidonic acid (49). Arachidonic acid, a substrate of 5-lipoxygenase, is involved in the production of LTB₄. Thus, as a possible mechanism, IL-31-induced Ca²⁺ influx is involved in the production of LTB₄.

LTB₄ directly activates DRG neurones and induces scratching (41, 50). The LTB₁ receptors, BLT1 and BLT2, have high and low binding affinities for LTB₄, respectively (51). The LTB₁ receptor antagonist CMHVA has a similar affinity for both receptors (51). The DRG neurones and skin in the normal mice expressed BLT1 receptor mRNA, but not BLT2 receptors (50). Most (81%) of the BLT1-immunoreactive DRG neurones are transient receptor potential vanilloid 1 (TRPV1), a marker of unmyelinated C-fibre neurones (50). Therefore, it is suggested that BLT1 receptor is involved in LTB₄-mediated IL31-induced scratching. A recent study showed that BLT2 antagonist, but not BLT1 receptor antagonist, inhibits LTB₄-induced scratching (52). However, our previous study has been shown that an intradermal injection of BLT2 receptor agonist (12(S)-hydroxy-(5Z, 8E, 10E)-heptadecatrienoic acid and CAY10538) did not induce scratching in mice (data not shown). Therefore, further study on the role of BLT2 in scratching will be necessary.

In this study, IL-31 receptors were expressed in the DRG neurones/primary afferents, suggesting that IL-31 directly activates the primary afferents. Cevikbas et al. showed that IL-31 acts on IL-31RA(+) /TRPV1(+) neurones (13). In addition, IL-31-induced scratching is attenuated in TRPV1-deficient mice (13). Our previous reports have shown that TRPV1-deficiency or -desensitization in primary sensory neurones abolish the scratching induced by pruritogens (e.g. substance P and serotonin) (27, 28) and allergy (e.g. mosquito allergy) (53). Taken together, TRPV1-positive sensory neurones play an important role in the itch signalling induced by IL-31 and LTB₄. IL-31 acts not only on IL-31RA(+) /TRPV1(+) neurones, but also on IL-31RA(+) /transient receptor channel potential cation channel ankyrin subtype 1 (TRPA1)(+) neurones (13). Fernandes et al. (52) showed that LTB₄-induced scratching is attenuated in both TRPV1- and TRPA1-deficient mice. Therefore, it is suggested that TRPA1-positive sensory neurones also play an important role in IL-31- and LTB₄-induced scratching.

In conclusion, IL-31 elicits itch not only through direct action on primary sensory neurones, but also by inducing LTB₄ production in keratinocytes.

ACKNOWLEDGEMENTS

The authors thank Chugai Pharmaceutical Co., Ltd for providing the mouse IL-31. This work was supported by a research grant from Chugai Pharmaceutical Co. Ltd, and partially supported by the Platform Project for Supporting in Drug Discovery and Life Science Research Platform for Drug Discovery, Informatics, and Structural Life Science from the Japan Agency for Medical Research and Development (AMED).

REFERENCES